Novavax, Inc. (NASDAQ:NVAX) SVP John Trizzino acquired 16,500 shares of Novavax stock in a transaction dated Monday, June 16th. The shares were purchased at an average cost of $4.51 per share, for a total transaction of $74,415.00. Following the purchase, the senior vice president now directly owns 16,500 shares in the company, valued at approximately $74,415. Novavax, Inc. (NASDAQ:NVAX) weekly performance is 2.51%. On last trading day company shares ended up $ 4.49. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average (SMA50) is 3.83%.
Insys Therapeutics Inc (NASDAQ:INSY) Director John N. Kapoor purchased 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 13th. The stock was purchased at an average price of $25.44 per share, with a total value of $127,200.00. Following the acquisition, the director now directly owns 15,991 shares in the company, valued at approximately $406,811. Insys Therapeutics Inc (NASDAQ:INSY) shares advanced 12.29% in last trading session and ended the day on $29.70. Gross Margin is 87.90% and its return on assets is 56.80%. Insys Therapeutics Inc (NASDAQ:INSY) quarterly performance is -37.70%.
Durata Therapeutics Inc (NASDAQ:DRTX) CEO Paul R Edick purchased 3,000 shares of Durata Therapeutics stock in a transaction dated Thursday, June 12th. The shares were purchased at an average price of $15.23 per share, for a total transaction of $45,690.00.Durata Therapeutics Inc (NASDAQ:DRTX) shares moved up 1.79% in last trading session and was closed at $16.45, while trading in range of $15.91 – $16.60. Durata Therapeutics Inc (NASDAQ:DRTX) year to date (YTD) performance is 28.62%.
Biota Pharmaceuticals Inc (NASDAQ:BOTA) CEO Russell H. Plumb purchased 32,031 shares of Biota Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $95,772.69. Following the acquisition, the chief executive officer now directly owns 127,579 shares in the company, valued at approximately $381,461. Biota Pharmaceuticals Inc (NASDAQ:BOTA) ended the last trading day at $3.22. Company weekly volatility is calculated as 9.05% and price to cash ratio as 2.20. Biota Pharmaceuticals Inc (NASDAQ:BOTA) showed a positive weekly performance of 20.15%.
ImmuCell Corporation (NASDAQ:ICCC) Director Jonathan E Rothschild purchased 5,901 shares of ImmuCell Corporation stock in a transaction dated Monday, June 16th. The shares were purchased at an average price of $4.57 per share, for a total transaction of $26,967.57.ImmuCell Corporation (NASDAQ:ICCC) net profit margin is 1.60% and weekly performance is 9.98%. On last trading day company shares ended up $4.41. ImmuCell Corporation (NASDAQ:ICCC) distance from 50-day simple moving average (SMA50) is 5.91%.